Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D 3 that resists the catalytic activity of both CYP27B1 and CYP24A1

Journal of Cellular Biochemistry

Volumn 115, Issue 8, 2014, Pages 1392-1402

  Rhieu, Steve Y ^a   Annalora, Andrew J ^b   Laporta, Erika ^c   Welsh, Joellen ^c   Itoh, Toshimasa ^d   Yamamoto, Keiko ^d   Sakaki, Toshiyuki ^e   Chen, Tai C ^f   Uskokovic, Milan R ^g   Reddy, G Satyanarayana ^a  

^a Epimer LLC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^e TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

16 ene 23 yne; antiproliferative activity; cyp24a1; cyp27b1; vitamin D

Indexed keywords

25 HYDROXY 16 ENE 23 YNE VITAMIN D3; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; 25-HYDROXY-16,23-DIENE VITAMIN D3; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; COLECALCIFEROL; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST TUMOR; CATALYSIS; CELL FREE SYSTEM; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME INACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; IMMORTALIZED CELL LINE; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VITAMIN D METABOLISM; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECALCIFEROL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MOLECULAR DOCKING SIMULATION; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; VITAMIN D3 24-HYDROXYLASE;

EID: 84902477454     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24789     Document Type: Article

References (63)

1. 3. Proc Natl Acad Sci USA 78: 4990-4994.
2. Akiyoshi-shibata M, Sakaki T, Ohyama Y, Noshiro M, Okuda K, Yabusaki Y,. 1994. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase: a study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 224: 335-343.
3. Annalora A, Bobrovnikova-Marjon E, Serda R, Lansing L, Chiu ML, Pastuszyn A, Iyer S, Marcus CB, Omdahl JL,. 2004. Rat cytochrome P450C24 (CYP24A1) and the role of F249 in substrate binding and catalytic activity. Arch Biochem Biophys 425: 133-146.
4. Annalora AJ, Goodin DB, Hong WX, Zhang QH, Johnson EF, Stout CD,. 2010. The crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J Mol Biol 396: 441-451.
5. 3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35: 8465-8472.
6. Bikle DD,. 1992. Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential. Endocr Rev 13: 765-784.
7. Bouillon R, Okamura WH, Norman AW,. 1995. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257.
8. Brown AJ,. 1998. Vitamin D analogues. Am J Kidney Dis 32: S25-S39.
9. Brumbaugh BF, Haussler MR,. 1975. Nuclear and cytoplasmic binding components for vitamin D metabolites. Life Sci 16: 353-362.
10. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas AG, Boland R, Ferrucci L, Bikle DD,. 2013. Vitamin D: beyond bone. Ann NY Acad Sci 1287: 45-58.
11. DeLuca HF, Prahl JM, Plum LA,. 2011. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys 505: 226-230.
12. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF,. 1973. Pathogenesis of hereditary vitamin-D-dependent Rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. N Engl J Med 289: 817-822.
13. + oxidoreductase. J Biol Chem 261: 12649-12654.
14. Gray RW, Omdahl JL, Ghazarian JG, DeLuca HF,. 1972. 25- Hydroxycholecalciferol-1-hydroxylase. Subcellular location and properties. J Biol Chem 247: 7528-7532.
15. Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L,. 2011. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperthyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 80: 841-850.
16. 3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Invest New Drugs 29: 1420-1425.
17. Johnson CS, Hershberger PA, Trump DL,. 2002. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev 21: 147-158.
18. Jones G,. 2012. Vitamin D analogs. Rheum Dis Clin North Am 38: 207-232.
19. Jones G, Prosser DE, Kaufmann M,. 2014. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55: 13-31.
20. Kimura T, Parcells JH, Wang HP,. 1978. Purification of adrenodoxin reductase, adrenodoxin, and cytochrome P-450 from adrenal cortex. Methods Enzymol 52: 132-142.
21. Krishnan AV, Trump DL, Johnson CS, Feldman D,. 2012. The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 38: 161-178.
22. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS,. 1997. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764.
23. 3 is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 118: 162-170.
24. 5. J Natl Cancer Inst 92: 1836-1840.
25. 5, a synthetic analog of vitamin D. Mutat Res 523-524: 253-264.
26. Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R,. 2012. Vitamin D and breast cancer: Emerging concepts. Cancer Lett 334: 95-100.
27. 3. J Biol Chem 272: 14115-14119.
28. Omura T, Sato R,. 1964. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239: 2379-2385.
29. Plum LA, DeLuca HF,. 2010. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9: 941-955.
30. 3 through the C-24 oxidation pathway. Biochemistry 28: 1763-1769.
31. 3 in neonatal human keratinocytes. Steroids 66: 441-450.
32. 3 metabolism in rat kidney through C-24 oxidation pathway. Arch Biochem Biophys 455: 18-30.
33. Rhieu SY, Ludwig DR, Siu VS, Palmore GTR,. 2009. Direct electrochemistry of cytochrome P450 27B1 in surfactant films. Electrochem Commun 11: 1857-1860.
34. 3. Arch Biochem Biophys 509: 33-43.
35. 3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70: 654-659.
36. Ritter CS, Brown AJ,. 2011. Direct suppression of PTH gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol 46: 63-66.
37. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS,. 2012. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 33: 456-492.
38. Sagara Y, Wada A, Takata Y, Waterman MR, Sekimizu K, Horiuchi T,. 1993. Direct expression of adrenodoxin reductase in Escherichia coli and the functional characterization. Biol Pharmacol Bull 16: 627-630.
39. 3 1α-hydroxylase expressed in Escherichia coli. Eur J Biochem 259: 731-738.
40. 3 to calcitroic acid. Eur J Biochem 262: 43-48.
41. 3 by cytochromes P450. Front Biosci 10: 119-134.
42. Schuster I,. 2011. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814: 186-199.
43. 3 and prostate cancer cell proliferation in vivo. Urology 46: 365-369.
44. 3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184.
45. 3 into their respective lactones. Endocrinology 136: 4195-4203.
46. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960.
47. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86: 709-714.
48. 3. J Mol Biol 380: 95-106.
49. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317-323.
50. 3, which has altered biological activity. Drug Metab Dispos 38: 1553-1559.
51. 3 1α-hydroxylase (CYP27B1). J Steroid Biochem Mol Biol 119: 171-179.
52. Tang EKY, Tieu EW, Tuckey RC,. 2012. Expression of human CYP27B1 in Escherichia coli and characterization in phospholipid vesicles. FEBS J 279: 3749-3761.
53. 3 metabolism by human and mouse CYP27B1. Drug Metab Dispos 41: 1112-1124.
54. Uchida E, Kagawa N, Sakaki T, Urushino N, Sawada N, Kamakura M, Ohta M, Kato S, Inouye K,. 2004. Purification and characterization of mouse CYP27B1 overproduced by an Escherichia coli system coexpressing molecular chaperonins GroEL/ES. Biochem Biophys Res Commun 323: 505-511.
55. Urushino N, Yamamoto K, Kagawa N, Ikushiro S, Kamakura M, Yamada S, Kato S, Inouye K, Sakaki T,. 2006. Interaction between mitochondrial CYP27B1 and adrenodoxin: role of arginine8 of mouse CYP27B1. Biochemistry 45: 4405-4412.
56. 3 hydroxylation by CYP27B1 and CYP24A1. Drug Metab Dispos 35: 1482-1488.
57. 3 that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 66: 463-471.
58. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C,. 2010. Vitamin D: a pleiotropic hormone. Kidney Int 78: 140-145.
59. Wang L, Flanagan JN, Whitlatch LW, Jamieson DP, Holick MF, Chen TC,. 2004. Regulation of 25-hydroxyvitamin D-1α-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol 89-90: 127-130.
60. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF,. 2004. The prostate-hydroxyvitamin D-1α- hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25: 967-971.
61. 3 receptor knockout mice. Mol Cell Endocrinol 200: 67-80.
62. Zhu J, DeLuca HF,. 2012. Vitamin D 25-hydroxylase-Four decades of searching, are we there yet?. Arch Biochem Biophys 523: 30-36.
63. Zhu JG, Ochalek JT, Kaufmann M, Jones G, DeLuca HF,. 2013. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci USA 110: 15650-15655.